Subject: BICX News Highlights the Moves of a Smart Young Company on the Rise

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
BICX News Highlights the Moves of a Smart Young Company on the Rise
Hot Stock to WatchHot Stock to Watch

Company: Biocorrx, Inc. (Pink Sheets: BICX)


Price: 0.0275

Change (%): + 0.0018 (7.00)

Volume: 89,115
BICX Chart

BioCorRx Launches R&D Initiative to Pursue FDA Approval for Naltrexone Implant

LOS ANGELES, CA--(Marketwired - Jul 14, 2016) - BioCorRx Inc. (OTCQB: BICX), developer of the BioCorRx® Recovery Program, a non-addictive medication-assisted treatment (MAT) program used in the treatment of alcohol and opioid addiction, announced today it is establishing a Research and Development initiative in order to seek U.S. Food and Drug Administration (FDA) approval for its naltrexone implant.

Naltrexone is a non-addictive opioid antagonist medicine that can significantly reduce physical cravings for alcohol and opioids in most people. It can also block some of the effects of those substances. The naltrexone implant works by slowly releasing the medicine into the body for several months.

BioCorRx's previously announced 2.5 million dollar investment with Alpine Creek will help to fund this R&D initiative. The Company also plans to separately utilize this R&D platform to evaluate other compounds with the objective of expanding its product pipeline in the rapidly evolving market for addiction treatment.

In May of this year, the FDA approved a buprenorphine implant which is used to treat opioid addiction. This implant, however, requires removal after 6 months and uses a medication that is a partial opioid agonist. In contrast, the naltrexone implant from BioCorRx is completely biodegradable and works by blocking opioid receptors in the brain and can be effective for both opioid addiction and alcoholism.

"While we continue to observe positive results in our practice, currently the FDA has not given a specific approval for the administration of naltrexone by having it implanted under the skin. Vivitrol, the first FDA approved 30-day injectable form of naltrexone, has led to meaningful market penetration, demonstrating strong demand for this application. Furthermore, with the recent approval of Probuphine by the FDA, implants to treat addiction in general are getting more exposure," said Brady Granier, CEO of BioCorRx. "Our objective is to expand the addressable market for our treatment targets and seeking FDA approval for our naltrexone implant is a logical next step. To support this endeavor, we anticipate announcing strategic relationships with experienced FDA advisors and consultants in the near term and will provide further details as our strategy unfolds."

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications. Small Cap Voice received 500 dollars from the company on 7-13-16 for a one day email campaign.

About Penny Stocks